340B Drug Pricing Program: Original Intent, Compliance Non-Negotiables, and What’s Changing Now

WATKINSVILLE, GA / ACCESS Newswire / September 30, 2026 / The rebate model is coming. Contract pharmacy restrictions aren’t going away. And the organizations that will weather it best are the ones preparing now.

The 340B Drug Pricing Program has been a financial lifeline for rural hospitals, critical access facilities, and community health centers for decades. But between evolving manufacturer restrictions, emerging rebate models, and growing scrutiny over how savings are used, the landscape is shifting – and quickly.

At PharmD on Demand®, we work directly with hospitals and health centers to manage, protect, and optimize their 340B programs. Here’s a full breakdown of where the program stands today.

What Was the 340B Program Originally Designed to Do?

The 340B program was created to give hospitals and health centers that serve a higher proportion of indigent patients access to significantly discounted prescription drug pricing. The core intent: save money, not make money – and use those savings to better serve the community.

That distinction matters more now than ever.

The savings generated through 340B allow eligible facilities to:

• Reduce drug spend and reinvest in expanded services
• Keep care local and reduce patient outmigration
• Serve underinsured and uninsured patients without sacrificing financial sustainability

For rural hospitals in particular, where patients may have no other nearby option for care, the 340B program provides the financial cushion needed to keep services open and accessible.

Why Rural and Safety Net Hospitals Need This Relief

Reimbursement in healthcare is complex, ever-changing, and deeply tied to the political climate. Rural and critical access hospitals frequently serve populations on Medicare, Medicaid, or no insurance at all – meaning they often can’t capture full reimbursement for the care they provide.

These aren’t hospitals chasing high profit margins. They’re not-for-profit facilities operating on razor-thin margins, doing essential work: treating the everyday health needs of their communities so that larger, higher-acuity systems remain accessible when patients need more complex care.

Without programs like 340B, many of these facilities simply couldn’t sustain the breadth of services their communities depend on.

Who Qualifies for the 340B Program?

Eligibility is rooted in the program’s original mission: identifying facilities that disproportionately serve vulnerable populations. Qualified covered entities generally include:

• Disproportionate Share Hospitals (DSH) that meet specific criteria related to their low-income patient volume
• Critical Access Hospitals (CAHs) designated as geographically isolated from other healthcare options
• Federally Qualified Health Centers (FQHCs) and Community Health Centers specifically designated to provide primary care, dental, and other services to underinsured and uninsured patients

Each of these entities plays a critical role in the broader healthcare ecosystem – and 340B is one of the key mechanisms that keeps them viable.

The Compliance Non-Negotiables

The financial benefit of 340B only exists as long as your program remains compliant. At PharmD on Demand®, compliance isn’t an afterthought – it’s the foundation of everything we do for our clients.

The Two Pillars of 340B Compliance

1. Diversion – 340B-priced drugs must only be dispensed to eligible patients at eligible locations. Giving 340B drugs to a patient who doesn’t qualify constitutes diversion and is a serious compliance violation.

2. Duplicate Discounts – Facilities must not receive both a 340B discount and a Medicaid rebate for the same drug. This is where the “carve in vs. carve out” decision becomes critical.

Carve In vs. Carve Out: Getting It Right from the Start

One of the first things PharmD on Demand® addresses with new clients is how they’re handling Medicaid:

• Carving in means billing 340B-purchased drugs to Medicaid fee-for-service
• Carving out means not billing 340B drugs to Medicaid at all

There’s no universal right answer – it depends on your state’s rules and your facility’s specific situation. But getting this decision wrong, or inconsistently applying it, creates significant compliance risk.

How We Support Ongoing Compliance

PharmD on Demand® conducts monthly audits and mock HRSA audits with our clients for two reasons: to verify ongoing compliance and to prepare facilities for a real HRSA audit at any time. We also coach staff on day-to-day eligibility assessments to make sure compliance is upheld at the operational level – not just on paper.

If you can’t operate your 340B program compliantly, you don’t have a program worth operating.

How Are Hospitals Using Their 340B Savings?

This has become one of the most scrutinized questions in the 340B space. As of now, there are no federal requirements to report how 340B savings are used – but that is beginning to change at the state level. Vermont, for example, now requires annual reporting on savings and how they were deployed.

The common concern is that savings are being funneled toward executive compensation or provider salaries rather than patient services. That narrative, while sometimes fair to examine, often misses the broader picture. Investing 340B savings in competitive salaries, quality administration, or operational infrastructure still serves the program’s intent – it keeps safety net providers financially sustainable and able to attract the talent needed to serve their communities.

What’s important is that facilities use their savings thoughtfully, can articulate how those savings align with the program’s mission, and stay ahead of evolving reporting requirements. Transparency – something PharmD on Demand® builds into every program we manage – is the best protection against scrutiny.

The Major Shifts Already Affecting 340B Covered Entities

Contract Pharmacy Restrictions

Over the last five to six years, drug manufacturers have aggressively moved to restrict or eliminate 340B pricing for drugs dispensed through contract pharmacies – community and chain pharmacies outside of a hospital’s or health center’s own four walls that are contracted to serve the covered entity’s patients.

For FQHCs and community health centers without an in-house retail pharmacy, these restrictions effectively gutted their 340B benefit. The response has been a surge in covered entities opening their own retail pharmacies – a space where PharmD on Demand® bridges pharmacy expertise with 340B program management to help facilities bring that capability in-house.

At the federal level, efforts to protect contract pharmacy access have seen mixed results state by state, but momentum is building. PharmD on Demand® is tracking these developments closely and believes federal-level protections are increasingly likely in the years ahead.

The Rebate Model: What’s Coming and How to Prepare

HRSA has revised the previously paused Rebate Pilot Program, and it will begin on January 1st, 2027. This revision will be expanded to 25 drugs, and largely mirror the program that was introduced, and subsequently paused, in 2025.. Rather than purchasing these drugs at the 340B discounted price upfront, covered entities will pay the higher market price and then receive a rebate from the manufacturer after submitting the required data.

This shift creates real operational and financial challenges:

• Cash flow disruption – Higher upfront drug costs will be followed by rebate payments. In the first months of the new model, covered entities will see elevated drug spend with little to no rebates yet coming in. For facilities already operating on tight margins, this gap is not a minor inconvenience – it can be critical. Manufacturers have 45 days to remit payment from the date of receiving claims data in Beacon.
• Data submission requirements – Facilities will need to demonstrate that the drug was purchased at the higher price, dispensed to an eligible patient, and submit that data through Beacon.. Many data elements are requiring extra time and preparation to determine how to provide for submission.
• Program-by-program complexity – HRSA is not running one unified rebate program. Each participating manufacturer runs their own, which adds operational layers for covered entities to manage.

What PharmD on Demand® Is Doing Right Now

We’ve already begun running month-by-month financial projections for our clients, analyzing their usage of the 25 affected drugs, which come from the 2026 and 2027 MFP Drug Lists, over the past year to model the cash flow impact of the rebate model before it takes effect. We’re not waiting to react – we’re preparing our clients today.

The organizations that will navigate these changes best are the ones who understand what’s coming, know their numbers, and have expert guidance in their corner.

The Bottom Line on 340B in 2027 and Beyond

The 340B program remains one of the most powerful tools available to rural hospitals, critical access facilities, and community health centers. But it’s also one of the most complex – and the regulatory environment around it is becoming more demanding, not less.

Compliance must come first. Savings must be used with intention and transparency. And with the rebate model on the horizon and contract pharmacy battles ongoing, the time to prepare is now.

At PharmD on Demand®, we help covered entities protect their 340B programs, stay ahead of compliance requirements, and navigate the changes that are already reshaping the landscape.

Want to understand where your 340B program stands – and what you should be doing now? Let’s talk. https://pharmdondemand.com/services/340b-program-support/

CONTACT: info@pharmdondemand.com

SOURCE: PharmD On Demand

View the original press release on ACCESS Newswire